Crescent Energy Company Class A Common Stock vs Cassava Sciences Inc — how do they compare? Crescent Energy Company Class A Common Stock trades at $12.66 (market cap $4.30B), while Cassava Sciences Inc trades at $0.82 (market cap $39.40M). The key difference: Crescent Energy Company Class A Common Stock is far larger — about 109.1× Cassava Sciences Inc's market cap, and Crescent Energy Company Class A Common Stock pays a 3.69% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Crescent Energy Company Class A Common Stock for 1 Days and Cassava Sciences Inc for 37 Days on average.
| CRGY | FLNA | |
|---|---|---|
Market Cap | $4.30B | $39.40M |
Volume | 15,201,625 | 759,018 |
Sector | Energy | Health |
52-Week High | $15.37 | $4.64 |
52-Week Low | $7.75 | $0.68 |
Typical Hold Time | 1 Days | 37 Days |
Enterprise Value | $9.31B | -$43.28M |
Dividend Yield | 3.69% | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
FLNA trades at $0.8136, down 0.26% today, with a bearish technical signal from moving averages but neutral oscillators. The company shows negative profitability with ROE at -55.79% and ROA at -35.34%, though it has beaten EPS estimates in recent quarters. Recent positive news includes FDA lifting a clinical hold on its epilepsy drug, enabling Phase 2a studies.
The outlook remains high-risk due to persistent negative cash flows and lack of revenue, but analyst consensus is bullish with 67% buy ratings. Key risks include clinical trial execution and funding needs, while the FDA decision provides a potential catalyst for long-term investors focused on biotech turnaround stories.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Crescent Energy acquires, develops, and produces oil and natural gas from onshore U.S. basins. Its portfolio includes producing assets with oil and natural gas exposure.
Read more on CRGY →Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →